A Phase II Clinical Trial of Diaziquone in the Treatment of Patients with Recurrent Endometrial Carcinoma A Gynecologic Oncology Group StudySlayton, Robert E., M.D.; Blessing, John A., Ph.D.; DiSaia, Philip J., M.D.; Phillips, George, M.D.American Journal of Clinical Oncology: December 1988 - Volume 11 - Issue 6 - p 612–613 Original Article: PDF Only Buy Abstract Author InformationAuthors Twenty-six patients with measurable endometrial cancer refractory to standard therapy received AZQ [1,4-cyclohex-adiene-l,4-dicarbamic acid, 2,5-bis(l-aziridmyl)3,6,dioxo, diethyl ester, NSC 182986] 22.5 mg/m2 diluted in 150 ml normal saline intravenously every three weeks. Thirteen patients experienced no toxicity and the dose in those patients was increased to 30 mg/m2 after the first course. The median number of courses given was 2.5 (range 1–9). The leukocyte count fell below 3000/μl in 12 patients, and below 1000/μl in two. The platelet count fell below 100,000/μl in 12 patients, and below 25,000/μl in one. Cumulative hematologic toxicity was not seen. One clinical complete response and one partial response were observed. Eight patients had stable disease. Median time to disease progression was 2 months. Median survival was 5.9 months. At this dose and schedule AZQ does not appear to have significant activity in recurrent endometrial cancer. From the Department of Medicine, Section of Medical Oncology, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL (R.E.S.); the Gynecologic Oncology Group, Cancer Research Scientist V, Roswell Park Memorial Institute, Buffalo, NY (J.A.B.); the Department of Obstetrics and Gynecology, Director, University of California, Irvine Cancer Center, Orange, CA (P.J.D.); and the Department of Ob-Gyn, Fitzsimmons Army Medical Center, Aurora, CO (G.P.). © Lippincott-Raven Publishers.